Tate & Lyle (TLYB) AI Stock Analysis

5 Followers

Tate & Lyle

(Frankfurt:TLYB)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Higher-Value Solutions GrowthA rising share of wins from higher-value solutions supports a more differentiated business mix and deeper customer integration. These formulation-led offerings can improve repeat purchasing and provide a durable platform for growth across health, affordability and clean-label applications.

Negative Factors

Net Margin CompressionThe sharp decline in net margin shows that recent revenue growth has not translated consistently into bottom-line earnings. Persistently lower profitability would reduce internal funding capacity, limit resilience against cost pressure and make earnings more sensitive to operating volatility.

Tate & Lyle (TLYB) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 2.48B
Dividend Yield: 3.42%
Average Volume (3M): 1,192
Price to Earnings (P/E): 25.2
Beta (1Y): -0.05
Revenue Growth: 12.36%
EPS Growth: 40.82%
Country: Germany
Employees: 4,840
Sector: Consumer Defensive
Sector Strength: 62
Industry: Packaged Foods

Tate & Lyle Business Overview & Revenue Model

Company Description

Established in 1903 and headquartered in London, United Kingdom, Tate & Lyle PLC is a global provider of specialized ingredients and solutions. The company caters to the food, beverage, and other industrial sectors across the United States, the Unite...

Tate & Lyle Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q2-2027)|% Change Since:0.00%|Next Earnings Date:May 27, 2027

Earnings Call SentimentPositive

The call was overall constructive and positive: Tate & Lyle returned to volume-led revenue growth, generated GBP 100 million of free cash flow, maintained full-year outlook and dividend progression, and reported strong momentum in Asia Pacific, the Americas, solutions, fiber and its new-business pipeline. These positives were tempered by a more challenging European market, muted consumer demand in Europe and North America, higher input-cost inflation, difficult upcoming customer contract negotiations and the continuing impact of the Middle East conflict.

Positive Updates

Return to Volume-Led Revenue Growth

In the first half, group revenue increased 1% and volume mix increased 3%. Excluding bulk sweeteners and co-products in Europe and tariff reimbursements in the U.S., revenue increased 2% and volume mix increased 4%.

Negative Updates

More Pronounced Middle East Conflict Impact

The Middle East conflict has lasted longer than anticipated, and its impact has become more pronounced, particularly in Europe.

Company Guidance

Tate & Lyle is maintaining its outlook for the full year ending the 31st of March 2027, previously described as flat EBITDA, excluding the GBP 20 million bio-gums delay; H2 versus H1 is not expected to show a significant step-up, while the company expects to pass-through cost inflation through 2027 calendar year framework agreements and offset cost inflation through procurement activities and operational discipline. The bio-gum consolidation project is on track, and completion of the sale to Ingredion is expected in the second half of calendar year 2027; fiber is expected to accelerate over the next 12 to 18 months.

Tate & Lyle Peers Comparison

Overall Rating

UnderperformOutperform

Sector (62)

Financial Indicators

DE:TLYB against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:FVA	68Neutral	GBP 74.70M	5.68	42.90%	1.68%	―	―
GB:ANP	65Neutral	GBP 84.47M	12.48	17.05%	2.42%	10.99%	37.97%
GB:ABF	63Neutral	GBP 14.04B	15.03	8.06%	3.18%	0.63%	-6.82%
Sector *	62Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
GB:SALT	43Neutral	GBP 13.36M	-3.74	626.84%	―	85.66%	46.90%

* Consumer Defensive Sector Average

Performance Comparison

DE:TLYB and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:TLYB	Tate & Lyle Plc	6.75	2.47	57.75%
GB:ABF	Associated British Foods Plc (UK)	1984.00	-168.85	-7.84%
GB:ANP	Anpario plc	524.00	32.15	6.54%
GB:FVA	Fevara Plc	143.00	17.25	13.71%
GB:SALT	MicroSalt plc	16.50	-41.50	-71.55%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Tate & Lyle AI Stock Analysis